Covenant Reach

Working hypothesis

v0.1.322

In MS, an advancing CNS-penetrant BTK lever (tolebrutinib lead; remibrutinib also advancing) aimed at B-cell and microglial immune drivers, paired with a watch-only selective M1 antagonist (PIPE-307) inside a secondary OPC-forward remyelination stack, might slow confirmed disability progression and yield supportive myelin-repair signals only if each lever shows separable benefit—an unproven dual-arm idea falsified if BTK fails disability endpoints or if PIPE-307/remyelination adds no independent repair or disability signal.

Architecture stays two-lever: Arm A immune (CNS-penetrant BTK) and Arm B remyelination (M1/OPC-forward), without collapsing into one molecule or elevating PIPE-307 beyond watch; tolebrutinib remains the lead advancing CNS-penetrant BTK with remibrutinib advancing, while frexalimab, fenebrutinib, CAR-T, sterol, EBV, and RBC-tolerance options stay watch and opicinumab dropped; new papers (MOGAD/ADEM case, MSC review, EBV–POTS case, regional DMT patterns, intermittent hypoxia, exercise review, demyelinating biobank, fingolimod-related HLH) do not re-rank Arm A/B leads, do not supply MS disability or repair readouts for PIPE-307 watch, and do not justify oncology/wellness drift or cure language—so Arm B and the remyelination stack remain secondary pending disability/repair data, uncertainty stays explicit, and the dual-arm falsifier is retained.

— Kept dual-lever CNS-penetrant BTK + secondary M1/OPC remyelination stack; no single-molecule collapse
— Advance tolebrutinib (lead) and remibrutinib on Arm A; hold PIPE-307 at watch only on Arm B with stack secondary
— New papers do not prove MS cure, disease modification, PIPE-307 watch efficacy, or dual-arm disability/repair benefit

Auto-rewritten on each high-signal paper · —

Dual-action architecture

CNS-penetrant BTK + remyelination stack

Relapsing and progressive MS — quiet the inflammatory driver and support myelin repair

Track EBV-restricted B-cell persistence as a causal pressure, not as a claimed cure

Immune driver

CNS-penetrant BTK inhibitor (B-cell + microglia)

brain-penetrant kinase / innate-adaptive tone

— peripheral and CNS B-cell signaling
— microglial inflammatory tone
— slowing confirmed disability progression
— lesion activity suppression

Oral, once-daily class preferred. Liver-safety watch is a hard gate (Hy’s Law, ALT). Do not treat anti-CD20 depletion as interchangeable with CNS BTK.

clinical (tolebrutinib nrSPMS; remibrutinib RMS ph3; class still heterogeneous)

Remyelination

OPC / M1-forward remyelination stack

oral small-molecule preferred; imaging-anchored

— M1 muscarinic antagonist (PIPE-307 class)
— EBP / CYP51 sterol-pathway OPC drivers
— GPR17 antagonist
— Clemastine-class antihistamine remyelination (watch, modest VEP signal)

early clinical (PIPE-307, clemastine, GPR17, EBP/CYP51) — biological activity, limited disability benefit to date

Design rules

Keep the immune-driver arm CNS-penetrant (BTK or equivalent microglia/B-cell tone)
Pair, do not substitute, a remyelination/OPC arm with independent biomarkers (VEP, MTR, myelin PET)
Do not absorb EBV vaccines, CAR-T, or HSCT into the BTK slot unless a hybrid is explicitly scoped

Exploratory R&D → potential combination DMT plus regenerative adjunct. Not a marketed cure.

Continuous search

Rotating Europe PMC, OpenAlex, and ClinicalTrials.gov across every research line. New options extract as papers land.

OpenAlex · 7 new / 8 found

optic neuritis multiple sclerosis · —

Diffuse Alveolar Hemorrhage in Statin-Associated Immune-Mediated Necrotizing Myopathy: A Rare and Fatal Complication

OpenAlex · low · —

Tumefactive MOGAD Mimicking Multiple Sclerosis: A Diagnostic Challenge

OpenAlex · high · —

Isolated Parenchymal Neurosarcoidosis with Vascular Involvement Mimicking Granulomatous Primary Central Nervous System Vasculitis

OpenAlex · low · —

A Case of Recurrent Anti-DPPX Encephalitis Associated with Chronic Lymphocytic Leukaemia

OpenAlex · low · —

Europe PMC · 0 new / 0 found

EBV-specific T cells multiple sclerosis · —

OpenAlex · 4 new / 8 found

Epstein-Barr virus vaccine multiple sclerosis · —

Europe PMC · 0 new / 0 found

GPR17 antagonist remyelination MS · —

ClinicalTrials.gov · 0 new / 0 found

PIPE-307 remyelination multiple sclerosis · —

OpenAlex · 0 new / 0 found

NEK7 NLRP3 multiple sclerosis · —